FDA Grants Full Approval For Genentech’s Acute Myeloid Leukemia Medicine Under the FDA’s Real-Time Oncology Review Pilot Program And Project Orbis Initiative
On October 16, 2020, the FDA granted full approval for our acute myeloid leukemia (AML) medicine.